

Anna Sureda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2988177/publications.pdf>

Version: 2024-02-01

255
papers

9,814
citations

50170

46
h-index

42291

92
g-index

268
all docs

268
docs citations

268
times ranked

8331
citing authors

#	ARTICLE	IF	CITATIONS
1	Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 440-443.	0.1	4
2	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	0.6	8
3	A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. <i>Bone Marrow Transplantation</i> , 2022, 57, 176-182.	1.3	1
4	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
5	Cost-Effectiveness Analysis of Axicabtagene Ciloleucef vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. <i>Cancers</i> , 2022, 14, 538.	1.7	4
6	The first steps towards a diverse and inclusive EBMT: a position paper. <i>Bone Marrow Transplantation</i> , 2022, 57, 343-346.	1.3	2
7	Cold Agglutinin Disease: A Distinct Clonal B-Cell Lymphoproliferative Disorder of the Bone Marrow. <i>Hemato</i> , 2022, 3, 163-173.	0.2	2
8	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. <i>Bone Marrow Transplantation</i> , 2022, 57, 742-752.	1.3	45
9	The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. <i>Leukemia</i> , 2022, 36, 1646-1653.	3.3	6
10	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. <i>Journal of Hematology and Oncology</i> , 2022, 15, 54.	6.9	26
11	Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2041-2051.	0.6	1
12	Clinical assessment of the Omicron outbreak in Europe and trends in morbidity and mortality from COVID-19 and cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18673-e18673.	0.8	1
13	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	0.8	40
14	Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. <i>British Journal of Haematology</i> , 2021, 192, 869-878.	1.2	43
15	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 58-66.	0.6	21
16	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party's EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 655-663.	1.3	7
17	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	5.1	46
18	Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma. <i>EJHaem</i> , 2021, 2, 112-114.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome. <i>Blood</i> , 2021, 137, 994-999.	0.6	30
20	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S�azary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1391-1401.	1.3	24
21	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced�stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high�risk patients from the ECHELON�1 study. <i>Hematological Oncology</i> , 2021, 39, 185-195.	0.8	12
22	A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 116.	0.7	23
23	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	0.6	6
24	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1919-1928.	1.3	13
25	Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot Study. <i>JMIR Formative Research</i> , 2021, 5, e26121.	0.7	8
26	The direct and indirect effects of COVID�19 pandemic in a real�life hematological setting. <i>Cancer Reports</i> , 2021, 4, e1358.	0.6	6
27	Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7519-7519.	0.8	1
28	Extramedullary multiple myeloma patient derived orthotopic xenograft with high disturbed genome: combined exhaustive molecular and therapeutic studies. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	5
29	Real�world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B�cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	1.3	73
30	Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8010-8010.	0.8	6
31	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	2.2	43
32	Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7569-TPS7569.	0.8	1
33	Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7518-7518.	0.8	11
34	SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment. <i>Cancers</i> , 2021, 13, 2412.	1.7	1
35	Dose intensity and treatment duration of bortezomib in transplant�ineligible newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 246-254.	1.1	2
36	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell�Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1959-1970.	0.8	228

#	ARTICLE	IF	CITATIONS
37	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37
38	O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data. <i>Annals of Oncology</i> , 2021, 32, S292.	0.6	0
39	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	0.6	23
40	Is Post-Transplant Cyclophosphamide the New Methotrexate?. <i>Journal of Clinical Medicine</i> , 2021, 10, 3548.	1.0	11
41	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
42	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7
43	Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2021, 5, 3418-3426.	2.5	17
44	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. <i>Lancet, The</i> , 2021, 398, 1157-1169.	6.3	159
45	Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Transplantation</i> , 2021, 2, 396-411.	0.3	0
46	Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. <i>British Journal of Haematology</i> , 2021, 192, 1020-1025.	1.2	1
47	Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
48	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	0.6	7
49	Assessment of Treatment Response By Iife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. <i>Blood</i> , 2021, 138, 544-544.	0.6	7
50	Allogeneic STEM Cell Transplantation in 45 Patients with Myelodysplastic Syndrome: Single-Center Analysis. <i>Blood</i> , 2021, 138, 4913-4913.	0.6	0
51	Real-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study. <i>Blood</i> , 2021, 138, 3850-3850.	0.6	0
52	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. <i>Blood</i> , 2021, 138, 2719-2719.	0.6	1
53	Safety and Efficacy of Tinostamustine in Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2472-2472.	0.6	0
54	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2-2.	0.6	16

#	ARTICLE	IF	CITATIONS
55	Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. <i>Cancers</i> , 2021, 13, 6125.	1.7	11
56	Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 317-324.	1.3	13
57	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 613-622.	1.3	15
58	Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document. <i>Bone Marrow Transplantation</i> , 2020, 55, 811-817.	1.3	6
59	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 796-803.	1.3	9
60	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 633-640.	1.3	5
61	Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution. <i>Leukemia and Lymphoma</i> , 2020, 61, 575-581.	0.6	3
62	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study. <i>British Journal of Haematology</i> , 2020, 188, 745-756.	1.2	20
63	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e77-e85.	2.0	41
64	Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. <i>European Journal of Haematology</i> , 2020, 104, 198-206.	1.1	3
65	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	0.8	175
66	Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin's lymphoma with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 483-484.	1.3	1
67	Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , 2020, 25, 69-75.	0.9	14
68	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e380.	1.2	3
69	Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. <i>Leukemia and Lymphoma</i> , 2020, 61, 2915-2922.	0.6	1
70	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020, 20, 1088.	1.1	12
71	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
72	Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. <i>Blood Cancer Journal</i> , 2020, 10, 103.	2.8	57

#	ARTICLE	IF	CITATIONS
73	Risk factors and outcome of COVID-19 in patients with hematological malignancies. <i>Experimental Hematology and Oncology</i> , 2020, 9, 21.	2.0	119
74	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	0.6	13
75	1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection. <i>Annals of Oncology</i> , 2020, 31, S992.	0.6	0
76	318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Annals of Oncology</i> , 2020, 31, S1366.	0.6	9
77	Handling the COVID-19 pandemic in the oncological setting. <i>Lancet Haematology</i> , the, 2020, 7, e365-e366.	2.2	12
78	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 2170-2179.	1.3	8
79	Efficacy of extended infusion of $\hat{1}^2$ -lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). <i>Trials</i> , 2020, 21, 412.	0.7	6
80	A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	10
81	Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1384.	1.0	7
82	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	0.6	76
83	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	3.4	39
84	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis. <i>Oncology and Therapy</i> , 2020, 8, 311-324.	1.0	1
85	Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1828-1832.	2.0	6
86	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	0.8	34
87	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 14.	2.8	16
88	What's behind chronic graft versus host disease incidence curves?. <i>Lancet Haematology</i> , the, 2020, 7, e83-e84.	2.2	1
89	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	1.2	19
90	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	2.0	17

#	ARTICLE	IF	CITATIONS
91	Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. <i>Blood</i> , 2020, 136, 45-46.	0.6	45
92	Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 46-48.	0.6	38
93	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-21.	0.6	4
94	Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years. <i>Blood</i> , 2020, 136, 9-10.	0.6	3
95	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	0.6	3
96	Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m ² and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex). <i>Blood</i> , 2020, 136, 8-9.	0.6	12
97	Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study. <i>Blood</i> , 2020, 136, 5-6.	0.6	9
98	Allogeneic Transplantation for Relapsed Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 365-380.	0.2	0
99	Correction to: Graft Failure. , 2020, , C1-C1.		1
100	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). <i>Blood</i> , 2020, 136, 32-33.	0.6	0
101	Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts. <i>Blood</i> , 2020, 136, 28-30.	0.6	3
102	Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
103	Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
104	Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
105	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. <i>Blood</i> , 2020, 136, 13-14.	0.6	0
106	Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-14.	0.6	1
107	CD20-TCB (RG6026), A NOVEL $\alpha\epsilon 2:1\alpha\epsilon$ -FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 92-93.	0.8	16
108	<scp>m7FLIPI</scp> and targeted sequencing in high-risk follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 564-568.	0.8	2

#	ARTICLE	IF	CITATIONS
109	CVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019, 6, e89-e99.	2.2	47
110	Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). <i>Annals of Oncology</i> , 2019, 30, 612-620.	0.6	88
111	Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 1-5.	2.0	9
112	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
113	S1622 TANDEM AUTOLOGOUSâ€REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGHâ€RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWPâ€EBMT. <i>HemaSphere</i> , 2019, 3, 749-750.	1.2	2
114	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
115	Allogeneic transplantation in elderly patients â‰¥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
116	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 999-1005.	1.2	29
117	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	2.0	15
118	Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 1522-1527.	0.6	2
119	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
120	Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update. <i>Blood</i> , 2019, 134, 3152-3152.	0.6	4
121	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. <i>Blood</i> , 2019, 134, 506-506.	0.6	6
122	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2871-2871.	0.6	20
123	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)? <i>Blood</i> , 2019, 134, 785-785.	0.6	0
124	Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile. <i>Blood</i> , 2019, 134, 3424-3424.	0.6	0
125	Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center. <i>Blood</i> , 2019, 134, 4270-4270.	0.6	1
126	Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2019, 134, 319-319.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers. <i>Blood</i> , 2019, 134, 5568-5568.	0.6	1
128	Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2019, 134, 3318-3318.	0.6	0
129	Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 3013-3013.	0.6	1
130	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	1.2	23
131	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
132	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	2.0	58
133	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
134	Brentuximab vedotin for lymphoma in paediatric patients. <i>Lancet Haematology</i> ,the, 2018, 5, e433-e434.	2.2	0
135	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. <i>Blood</i> , 2018, 132, 2639-2642.	0.6	172
136	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
137	Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , 2018, 124, 3455-3456.	2.0	0
138	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , 2018, 132, 226-226.	0.6	24
139	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3245-3245.	0.6	17
140	Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2018, 132, 3429-3429.	0.6	0
141	Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. <i>Leukemia and Lymphoma</i> , 2017, 58, 222-225.	0.6	6
142	Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 452-454.	1.3	4
143	Actualizaci3n del diagn3stico y el tratamiento de la leucemia/linfoma T del adulto. <i>Medicina Cl3nica</i> , 2017, 148, 176-180.	0.3	1
144	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28

#	ARTICLE	IF	CITATIONS
145	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , 2017, 35, 520-527.	0.8	20
146	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20
147	Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. <i>Leukemia</i> , 2017, 31, 1752-1759.	3.3	23
148	CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like. <i>Hematological Oncology</i> , 2017, 35, 290-290.	0.8	1
149	Effective treatments are required for patients with diffuse large B-cell lymphoma (DLBCL) with primary refractory disease. <i>Hematological Oncology</i> , 2017, 35, 344-344.	0.8	0
150	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	135
151	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3425-3432.	0.8	132
152	Outcome of Haploidentical Stem Cell Transplantation in Patients with Lymphoma. <i>Pancreatic Islet Biology</i> , 2017, , 119-140.	0.1	0
153	Eight Cycles of ABVD Versus Four Cycles of BEACOPP_{escalated} Plus Four Cycles of BEACOPP_{baseline} in Stage III to IV, International Prognostic Score \geq 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2028-2036.	0.8	111
154	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	0.6	246
155	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , 2016, 27, 2251-2257.	0.6	40
156	Mesenchymal stromal cells for steroid-refractory acute GVHD. <i>Lancet Haematology</i> , the, 2016, 3, e8-e9.	2.2	3
157	Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually. <i>Bone Marrow Transplantation</i> , 2016, 51, 786-792.	1.3	338
158	Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 58-66.	1.3	36
159	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. <i>Bone Marrow Transplantation</i> , 2015, 50, 1037-1056.	1.3	283
160	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1853-1862.	6.3	633
161	A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1416-1423.	1.3	45
162	Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 744-750.	1.3	145

#	ARTICLE	IF	CITATIONS
163	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. <i>Blood Cancer Journal</i> , 2014, 4, e236-e236.	2.8	54
164	Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. <i>Bone Marrow Transplantation</i> , 2014, 49, 1266-1268.	1.3	68
165	The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. <i>Annals of Oncology</i> , 2014, 25, 2224-2229.	0.6	23
166	Lymphoma-directed conditioning for aggressive lymphoma. <i>Lancet Oncology</i> , The, 2014, 15, 678-679.	5.1	0
167	Prophylaxis and treatment of GVHD: EBMTâ€™ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , 2014, 49, 168-173.	1.3	252
168	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 865-872.	1.3	151
169	Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2014, 49, 671-678.	1.3	18
170	The Role of Allogeneic Stem Cell Transplantation in Hodgkinâ€™s Lymphoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 238-247.	1.3	13
171	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
172	The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 673-673.	0.6	10
173	Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 2430-2434.	0.6	89
174	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1409-1414.	1.3	63
175	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	0.8	206
176	Hematopoietic SCT in Europe: data and trends in 2011. <i>Bone Marrow Transplantation</i> , 2013, 48, 1161-1167.	1.3	110
177	Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. <i>Blood</i> , 2013, 122, 2094-2094.	0.6	2
178	Secondary Malignancies After Autologous Stem Cell Transplantation In Patients With Relapsed / Refractory Hodgkin's Lymphoma. A Retrospective Analysis On Behalf Of The Lymphoma Working Party Of The European Society For Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2013, 122, 4636-4636.	0.6	2
179	A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation. <i>Blood</i> . 2013. 122. 4648-4648.	0.6	10
180	Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party. <i>Blood</i> , 2013, 122, 3398-3398.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Use Of a Quality Management System and Outcome After Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 2945-2945.	0.6	1
182	The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 2012, 24, 727-732.	1.1	22
183	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317.	1.7	194
184	Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2012, 23, 166-171.	0.6	53
185	Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC). <i>Blood</i> , 2012, 120, 3949-3949.	0.6	0
186	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2012, 120, 3105-3105.	0.6	0
187	Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). <i>Blood</i> , 2012, 120, 1630-1630.	0.6	0
188	Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry. <i>Journal of Clinical Oncology</i> , 2011, 29, 1342-1348.	0.8	196
189	Stem Cell Transplantation Can Provide Durable Disease Control in Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC): A Retrospective Study From the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 3077-3077.	0.6	1
190	Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,. <i>Blood</i> , 2011, 118, 3938-3938.	0.6	2
191	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATCL): A Retrospective Study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 3115-3115.	0.6	0
192	High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 630-630.	0.6	0
193	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. <i>Haematologica</i> , 2010, 95, 1176-1182.	1.7	63
194	Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. <i>Bone Marrow Transplantation</i> , 2010, 45, 219-234.	1.3	297
195	Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5074-5080.	0.8	154
196	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. <i>Blood</i> , 2010, 116, 1910-1910.	0.6	2
197	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. <i>Blood</i> , 2010, 116, 307-307.	0.6	19
198	Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 363-363.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2010, 116, 419-419.	0.6	18
200	Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma?: a Retrospective Study From the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2010, 116, 688-688.	0.6	14
201	Prophylaxis and Treatment of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation: A Survey on Center Strategies by the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 1261-1261.	0.6	1
202	DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study. <i>Blood</i> , 2010, 116, 2397-2397.	0.6	0
203	Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. <i>Haematologica</i> , 2009, 94, 230-238.	1.7	161
204	Risk score for outcome after allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2009, 115, 4715-4726.	2.0	337
205	Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009, 114, 2060-2067.	0.6	70
206	Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)à, Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeà, as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.. <i>Blood</i> , 2009, 114, 130-130.	0.6	24
207	A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years. <i>Blood</i> , 2009, 114, 3-3.	0.6	13
208	Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning (RIC-allo) in Patients with Relapsed or Refractory Hodgkin's Lymphoma (HL). Final Analysis of the HDR-Allo Protocol – A Prospective Clinical Trial by the Grupo Español de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2009, 114, 658-658.	0.6	5
209	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.. <i>Blood</i> , 2009, 114, 663-663.	0.6	24
210	Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant.. <i>Blood</i> , 2009, 114, 923-923.	0.6	12
211	Autologous and Allogeneic Stem Cell Transplantation for Richter's Transformation: A Retrospective Analysis From the Chronic Leukaemia Working Party and Lymphoma Working Party of the EBMT.. <i>Blood</i> , 2009, 114, 3360-3360.	0.6	0
212	The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.. <i>Blood</i> , 2009, 114, 3375-3375.	0.6	0
213	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. <i>Blood</i> , 2009, 114, 1113-1113.	0.6	0
214	Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 1811-1811.	0.6	1
215	Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).. <i>Blood</i> , 2009, 114, 874-874.	0.6	0
216	Allogeneic transplantation for Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 468-480.	1.2	20

#	ARTICLE	IF	CITATIONS
217	Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 455-462.	0.8	300
218	Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival.. <i>Blood</i> , 2008, 112, 3277-3277.	0.6	2
219	Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2008, 112, 457-457.	0.6	5
220	Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 774-774.	0.6	5
221	Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2008, 112, 458-458.	0.6	0
222	Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. <i>Blood</i> , 2008, 112, 4289-4289.	0.6	0
223	Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. <i>Blood</i> , 2008, 112, 4136-4136.	0.6	0
224	Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study. <i>Blood</i> , 2008, 112, 161-161.	0.6	0
225	Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor.. <i>Blood</i> , 2008, 112, 2229-2229.	0.6	0
226	Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2008, 112, 974-974.	0.6	0
227	Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. <i>Journal of Medical Economics</i> , 2007, 10, 27-39.	1.0	12
228	Autologous and Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 943-960.	0.9	12
229	Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. <i>Leukemia</i> , 2007, 21, 2324-2331.	3.3	138
230	A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): Identification of two populations with different outcomes. <i>Journal of Clinical Oncology</i> , 2007, 25, 8021-8021.	0.8	4
231	Anti-Thymocyte Globulin Induces Higher Response Rates and Less Graft-Versus-Host Disease in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 2980-2980.	0.6	1
232	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. <i>Blood</i> , 2007, 110, 4925-4925.	0.6	0
233	Comparison of Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate in Reduced Intensity Conditioning HLA Sibling Allogeneic Stem Cell Transplantation. A Case-Match Single-Center Experience.. <i>Blood</i> , 2007, 110, 4994-4994.	0.6	0
234	Prognostic Value of Immunophenotyping of Multiple Myeloma: A Study on 685 Patients Uniformly Treated with High-Dose Therapy.. <i>Blood</i> , 2007, 110, 1472-1472.	0.6	0

#	ARTICLE	IF	CITATIONS
235	The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3014-3014.	0.6	0
236	Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. Biology of Blood and Marrow Transplantation, 2006, 12, 172-183.	2.0	135
237	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. Blood, 2006, 108, 3086-3086.	0.6	3
238	Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Annals of Oncology, 2005, 16, 625-633.	0.6	198
239	Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma Patients.. Blood, 2005, 106, 2676-2676.	0.6	1
240	Influence of Age on Survival after a Tandem Hematopoietic Stem Cell Transplantation Procedure in Patients with Multiple Myeloma: Results of the Prospective GEM-2000 Protocol.. Blood, 2004, 104, 930-930.	0.6	2
241	Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Annals of Hematology, 2003, 82, 1-13.	0.8	17
242	Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. Annals of Hematology, 2003, 82, 127-130.	0.8	46
243	Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica, 2003, 88, 1213-20.	1.7	29
244	Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. Annals of Oncology, 2002, 13, 128-132.	0.6	25
245	Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. Journal of Clinical Oncology, 2001, 19, 1395-1404.	0.8	225
246	Intensified Prophylaxis of Febrile Neutropenia with Ofloxacin Plus Rifampin During Severe Short-Duration Neutropenia in Patients with Lymphoma. Leukemia and Lymphoma, 1999, 34, 585-589.	0.6	8
247	Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis. Bone Marrow Transplantation, 1999, 24, 1285-1290.	1.3	15
248	The management of chronic myeloid leukaemia - a case history. Annals of Oncology, 1997, 8, 91-96.	0.6	0
249	Listeriosis in Bone Marrow Transplant Recipients. Clinical Infectious Diseases, 1996, 23, 419-420.	2.9	13
250	Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. Leukemia and Lymphoma, 1996, 20, 321-326.	0.6	3
251	Infection by <i>Listeria monocytogenes</i> in the early period post-bone marrow transplantation. European Journal of Haematology, 1994, 53, 251-252.	1.1	3
252	Treatment of Refractory and Relapsed Adult Acute Leukemia Using a Uniform Chemotherapy Protocol. Leukemia and Lymphoma, 1993, 11, 393-398.	0.6	7

#	ARTICLE	IF	CITATIONS
253	High-Dose Chemotherapy with Bone Marrow Rescue for Treatment of Hodgkin's Disease. Leukemia and Lymphoma, 1992, 7, 29-31.	0.6	7
254	GM-CSF administration enhances granulocytic recovery in purged autologous bone marrow transplantation for acute lymphoblastic leukemia. Progress in Clinical and Biological Research, 1992, 377, 315-20.	0.2	0
255	Hodgkin Lymphoma: Recent Progress in Overall Management. , 0, , 83-116.		0